LENALIDOMIDE
Manner of administration:Oral
Restriction
Indication: Multiple myeloma
Treatment phase: Initial treatment in combination with dexamethasone, of newly diagnosed disease in
a patient ineligible for stem cell transplantation
Restriction
Indication: Multiple myeloma
Treatment phase: Continuing treatment until progression in patients initiated on dual combination therapy
(this drug and dexamethasone), or, in patients initiated on triple therapy (this drug,
bortezomib and dexamethasone during treatment cycles 1 up to 8) and are now being
treated with treatment cycle 9 or beyond
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 21 | # of repeats: 0 | DPMQ: $620.55 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Lenalide | |||||
| Lenalidomide Dr.Reddy's | |||||
| Lenalidomide Sandoz | |||||
| Revlimid | |||||